Current status and controversies in the management of borderline resectable pancreatic cancer
10.3760/cma.j.issn.1673-9752.2018.07.008
- VernacularTitle:可能切除胰腺癌治疗的现状与争议
- Author:
Chunyi HAO
1
;
Xubao LIU
;
Bei SUN
;
Tingbo LIANG
;
Xueli BAI
;
Xinlong WANG
Author Information
1. 100142,北京大学肿瘤医院肝胆胰外科
- Keywords:
Pancreatic neoplasms;
Pancreatic cancer;
Resectable;
Borderline resectable;
Direct surgery;
Neoadjuvant therapy
- From:
Chinese Journal of Digestive Surgery
2018;17(7):677-681
- CountryChina
- Language:Chinese
-
Abstract:
The borderline resectable pancreatic cancer is high a controversial hotspot in the field of pancreatic surgery,and the controversy mainly focuses on definition and treatment.Five famous experts and their teams in pancreatic surgery discussed present situation and dilemmas in treatment of borderline resectable pancreatic cancer based on clinical experiences.Professor Hao Chunyi has reviewed and analyzed origin of the definition and treatment model of borderline resectable pancreatic cancer,and proposed that high-level pancreatic disease center and multidisciplinary collaboration diagnosis and treatment may be the best choice for resectable pancreatic cancer.Professor Liu Xubao suggested surgical treatment for most of borderline resectable pancreatic cancer,and whether or not tumor invades adjacent blood vessels and invasion level will be used to decide direct surgery or neoadjuvant therapy.Professor Sun Bei proposed 6 causes,and direct surgery may be more realistic and feasible option for borderline resectable pancreatic cancer.Professors Liang Tingbo and Bai Xueli recommended that neoadjuvant therapy should be performed due to defeat hiding micrometastasis lesions and reduce tumor burden,and there was a higher R0 resection rate and lower lymph node metastasis rate after neoadjuvant therapy,meanwhile,it can also increase cure rate and is benefited to survival.
